- Home
- PWRL vs STTK Comparison
PWRL vs STTK Comparison
Compare PWRL & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PWRL | STTK |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 658.6M | 538.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PWRL | STTK |
|---|---|---|
| Price | $14.27 | $6.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 195.4K | ★ 1.7M |
| Earning Date | N/A | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.77 | $0.71 |
| 52 Week High | $16.31 | $8.33 |
Technical Indicators
Market Signals| Indicator | PWRL | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 44.20 | 62.05 |
| Support Level | $12.77 | $5.81 |
| Resistance Level | $16.18 | $7.68 |
| Average True Range (ATR) | 1.28 | 0.61 |
| MACD | 0.03 | 0.22 |
| Stochastic Oscillator | 46.89 | 80.62 |
Price Performance
Historical ComparisonAbout PWRL Powerlaw Corp. Common Stock
Powerlaw Corp is a non-diversified, closed-end management investment company. The Fund's investment objective is long-term capital appreciation. It seeks to achieve its investment objective by investing in the equity and equity-linked securities of a concentrated portfolio of approximately 12 to 15 late-stage technology companies.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.